

# HIV in Women

This is a PDF version of the following document:

Module 6: [Key Populations](#)

Lesson 3: [HIV in Women](#)

You can always find the most up-to-date version of this document at  
<https://www.hiv.uw.edu/go/key-populations/women-hiv/core-concept/all>.

---

## Background

Women comprise more than half of the people with HIV worldwide and almost 22% of persons with HIV in the United States.[1,2,3] Medical providers who care for women with HIV should be aware of the unique health care needs of this special population. This Topic Review will explore several of the most important clinical issues for women with HIV, including selection of appropriate antiretroviral therapy in women, contraception options, management of conception in serodifferent couples desiring pregnancy, gynecologic disorders, and menopause, and intimate partner violence. The following topics also pertain to women with HIV but are addressed in separate Lessons: (1) HIV in pregnancy ([Preventing Perinatal HIV Transmission](#)) and (2) cervical and breast cancer screening ([Primary Care Management](#)).

## **HIV Epidemiology in Women**

The following summary highlights key features of HIV epidemiology of women in the United States. These data are specifically for adult and adolescent women.

### **Estimated HIV Prevalence in Females with Diagnosed and Undiagnosed HIV**

At year-end 2021 in the United States, an estimated 21.9% (265,900 of 1,212,400) of adults and adolescents living with HIV in the United States were female.<sup>[4]</sup> These HIV prevalence estimates include females living with diagnosed and undiagnosed HIV.<sup>[4]</sup> In 2021, an estimated 9.8% of females with HIV in the United States had undiagnosed infection.<sup>[4]</sup> For all females with HIV in 2021 in the United States, 80.0% acquired HIV through heterosexual sex and 19.4% from injection drug use ([Figure 1](#)).<sup>[4]</sup>

### **Estimated HIV Incidence (New HIV Infections in Females)**

Females accounted for approximately 6,200 (19.3%) of the estimated 32,100 new HIV infections during the year 2021 in the United States.<sup>[4]</sup> For those women with new HIV infections in 2021, more than 80% acquired HIV through heterosexual sex ([Figure 2](#)).<sup>[4]</sup> Among the 6,200 new infections in adult and adolescent women and girls, 3,800 (61%) were Black individuals, and 1,200 (19%) were Hispanic individuals.<sup>[4]</sup>

### **Deaths in Women with HIV**

In the United States in 2021, there were 4,743 deaths from any cause in females with HIV.<sup>[5]</sup> Although the number of deaths from AIDS-related complications in the United States is now very low, deaths from any cause in both women and men with HIV have increased in recent years, primarily due to an aging population of persons living with HIV.

# Antiretroviral Therapy in Women

## Indications for Antiretroviral Therapy

The Adult and Adolescent ART Guidelines recommend antiretroviral therapy for all women with HIV to improve the health of the individual woman and to decrease the risk of sexual transmission of HIV.[6] This recommendation is the same as for all other adults and adolescents with HIV.[7] Women who are pregnant have the additional goal of using antiretroviral therapy to prevent perinatal transmission of HIV.[6]

## Efficacy

Available evidence suggests that virologic responses to antiretroviral therapy are comparable among women and men.[8,9] There are, however, some differences in women and men with respect to antiretroviral medication pharmacokinetics and adverse effects, which may be due to a wide range of factors such as body weight, plasma volume, and cytochrome P450 activity.[6,10,11,12] For example, postmenopausal women with HIV who are taking antiretroviral therapy have a particularly high risk of developing osteopenia and osteoporosis.[13,14,15,16] In addition, a recent pooled analysis of eight randomized clinical trials showed an increased weight gain for persons taking antiretroviral regimens containing integrase strand transfer inhibitors (specifically dolutegravir or bictegravir) and/or tenofovir alafenamide, with women having a 1.52-fold greater risk than men of developing a 10% or greater weight gain.[17] The reasons for these differences among women and men in weight gain are not clearly known at this time.[18,19,20]

## Selecting an Antiretroviral Regimen in Women of Childbearing Age

For women of childbearing age, it is important to carefully choose an antiretroviral regimen, taking into account multiple factors, including regimen efficacy, hepatitis B status, potential pharmacokinetic interactions (with hormonal contraceptives and hormone replacement therapy), and any teratogenicity concerns about the antiretroviral medications in the event of pregnancy.[6] All instances of antiretroviral exposure during pregnancy should be reported online to the [Antiretroviral Pregnancy Registry](#). For pregnant women with HIV, the Perinatal HIV Clinical Guidelines recommend using combination antiretroviral therapy (with at least 3 drugs) to reduce the risk of HIV transmission to the child and to prevent HIV-related disease in the mother.[21,22] The use of antiretroviral medications in pregnant women is discussed in detail in the lesson [Preventing Perinatal HIV Transmission](#) in Module 5. The following highlights commonly used preferred antiretroviral medications in adults and adolescent women that may have specific issues pertinent if a woman becomes pregnant while taking one or more of these medications.[23,24]

- **Bictegravir:** Bictegravir is a preferred integrase strand inhibitor drug for use during pregnancy due to its high viral suppression rates, good tolerability, high resistance barrier, and coformulation with the preferred dual-NRTI backbone (tenofovir alafenamide-emtricitabine) in a once-daily pill. Although pharmacokinetic studies have shown that bictegravir exposure is lower in the second and third trimesters, levels remain adequately therapeutic and effective for viral suppression without requiring dose adjustment.[25] Two different studies involving a total of 291 pregnancies in the United States showed high maternal viral suppression and reassuring birth outcomes, supporting its safety and effectiveness during pregnancy.[26]
- **Dolutegravir:** Preliminary data from an observational surveillance study of birth outcomes in a cohort of pregnant women with HIV in Botswana who received dolutegravir showed a slightly higher rate of neural tube defects in infants born to pregnant women receiving dolutegravir.[27] Subsequently, two additional studies found no significant increase in prevalence rates of neural tube defects among pregnant women taking dolutegravir-containing antiretroviral regimens compared to pregnant women with HIV taking antiretroviral regimens without dolutegravir.[28] Taking into account the updated data, the Perinatal HIV Clinical Guidelines now recommend dolutegravir as a preferred regimen, both for pregnant women (irrespective of pregnancy trimester) and for women trying to conceive (assuming they have not previously taken cabotegravir for HIV preexposure prophylaxis)

(PrEP).[\[22,29,30\]](#)

- **Cobicistat-Containing Regimens:** The antiretroviral regimens that contain darunavir-cobicistat or elvitegravir-cobicistat have been shown to have an increased risk of virologic failure in the second and third trimester of pregnancy, primarily due to lowered drug levels of these medications.[\[31\]](#) Thus, cobicistat-containing regimens are not recommended as initial antiretroviral therapy in people of childbearing age. If a woman becomes pregnant while taking a fully suppressive antiretroviral regimen that contains cobicistat, two options exist: (1) the regimen may be continued, provided there is frequent viral load monitoring throughout the pregnancy, or (2) the regimen can be switched to a more effective and preferred regimen for use during pregnancy.[\[23,32\]](#)
- **Darunavir:** Studies have shown that darunavir levels significantly decline during pregnancy, even when given with a booster.[\[33,34\]](#) Hence, the dose recommendation for darunavir use in pregnancy is 600 mg twice daily given with ritonavir 100 mg twice daily. In addition, darunavir-cobicistat should not be initiated during pregnancy due to concern for lowered drug levels associated with cobicistat use.[\[22\]](#) If, however, a woman becomes pregnant while taking a fully suppressive antiretroviral regimen that contains darunavir-cobicistat, the regimen may be continued (provided there is frequent plasma HIV RNA level monitoring throughout the pregnancy), or it can be switched to a more effective and preferred regimen for use during pregnancy.[\[22,32\]](#) Darunavir, boosted with ritonavir, is a preferred anchor drug for pregnant women, regardless of trimester, and for persons trying to conceive, especially for those individuals who have a history of receiving cabotegravir for HIV PrEP.[\[22\]](#) If once-daily dosing of darunavir-ritonavir is used in a woman trying to conceive, and she becomes pregnant, the dose should be increased to twice daily.[\[22\]](#)
- **Oral Two-Drug Therapy:** For the FDA-approved two-drug antiretroviral regimens (dolutegravir-lamivudine and dolutegravir-rilpivirine), there are limited data on use in pregnancy. Therefore, these two-drug regimens are not recommended for initiation during pregnancy, nor should they be used as first-line combination antiretrovirals in treatment-naïve women who are actively trying to conceive.[\[23\]](#) If a woman becomes pregnant while taking either dolutegravir-lamivudine or dolutegravir-rilpivirine, the clinician can consider continuing the same two-drug regimen, provided the pregnant woman has an undetectable HIV RNA level.[\[23\]](#) Alternatively, the pregnant woman can be switched to a preferred three-drug antiretroviral regimen that is recommended in pregnancy. If the decision is made to continue the same two-drug regimen, then HIV RNA levels must be monitored more frequently, typically every 1 to 2 months.[\[23\]](#)
- **Long-Acting Injectable Cabotegravir and Rilpivirine:** Data for long-acting injectable cabotegravir and rilpivirine use in pregnancy are extremely limited. There are some limited safety data for women found to be pregnant while taking injectable cabotegravir for HIV PrEP, but these women were all switched to full three-drug combination antiretroviral regimens once pregnancy status was verified.[\[35\]](#) As such, the combination long-acting injectable regimen cabotegravir and rilpivirine is not recommended as a first-line regimen for treatment-naïve pregnant women. For women who become pregnant while taking long-acting cabotegravir and rilpivirine, expert consultation should be obtained. These women may be switched to a preferred oral three-drug combination antiretroviral regimen, although the timing of switching will need to factor in the long half-life of the injectable cabotegravir and rilpivirine.[\[23\]](#) Women who become pregnant when taking long-acting cabotegravir and rilpivirine and who choose to remain on the injectable therapy will need more frequent (every 1-2 months) viral load monitoring during their pregnancy.[\[32\]](#)

## Contraception in Women with HIV

Health care providers should offer all women with HIV counseling about family planning, reproductive goals, and contraception options, and they should emphasize the importance of HIV prevention measures, including treatment as prevention, limiting the number of sex partners, correct and consistent use of condoms, and availability of HIV preexposure (PrEP) and HIV postexposure (PEP) prophylaxis for their partners, regardless of the method of contraception chosen. Discussing the risks of HIV transmission with different forms of contraception, as well as possible drug interactions with contraceptives and antiretroviral therapy, is also critical.

### Guidance for Hormonal Contraceptive Use

There are a number of excellent resources for guidance related to contraception in women with HIV, including the Centers for Disease Control and Prevention U.S. Medical Eligibility Criteria for Contraceptive Use (CDC U.S. MEC), the Perinatal HIV Clinical Guidelines, and the Adult and Adolescent ART Guidelines.[\[6,36,37,38\]](#) These resources provide recommendations about the safety and efficacy of different methods of contraception, prescribing recommendations, drug interactions, and counseling about family planning for women with or at risk of acquiring HIV. All of these guidelines concur that women with HIV should be offered a full array of contraception choices, including hormonal options.[\[36,37,39\]](#) Clinicians should use shared decision-making when selecting a contraceptive method in women with HIV, taking into account the patient's desires regarding family planning, a preferred contraceptive method, antiretroviral therapy regimen, other medications and comorbid conditions, and the risk of HIV transmission to sex partners.[\[36,38,39\]](#) The following summarizes the 2020 CDC U.S. MEC recommendations for the use of contraception in women with HIV:[\[38,39,40\]](#)

#### CDC U.S. MEC Categories for Classifying Contraceptive Methods

The CDC U.S. MEC uses a rating system to categorize the relative risks and benefits of each method of contraception depending on a woman's medical comorbidities or medication use.[\[38\]](#)

- 1 = A condition for which there is no restriction for the use of the contraceptive method.
- 2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.
- 3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.
- 4 = A condition that represents an unacceptable health risk if the contraceptive method is used.

#### CDC U.S. MEC Recommendations for Contraceptive Methods

- **Hormonal Contraceptives:** In these guidelines, hormonal contraceptives consist of combined hormonal contraceptives (including combined oral contraceptives, combined hormonal patches, and the combined vaginal ring), progestin-only pills, and implants. In women living with HIV who are not clinically well or not on antiretroviral therapy, combined hormonal contraceptives, progestin-only pills, and implants may be used without restriction (category 1). In women with HIV who are taking antiretroviral therapy, these contraceptives are considered safe, and the advantages of their use are thought to outweigh the risks. These are rated either CDC U.S. MEC category 1 or 2, depending on which antiretroviral therapy regimen the woman is using, due to concerns about drug interactions between contraceptives and some antiretroviral medications, especially protease inhibitors, pharmacologic boosters, and efavirenz.
- **Progestin-Only Injectable Contraceptives:** In women with HIV, progestin-only injectable contraceptives are considered safe to use without restriction (category 1). Most often, depot-medroxyprogesterone acetate (DMPA) is the progestin-only injectable contraceptive used. Antiretroviral medication drug interactions with DMPA are generally not clinically significant. There continues to be some evidence of a possible increased risk of HIV transmission and acquisition, but

the CDC continues to recommend DMPA (without restriction) in women living with HIV. The CDC has updated its recommendations about the use of DMPA in women at high risk of acquiring HIV.

- **Intrauterine devices (IUDs):** Intrauterine devices (IUDs) are considered safe and effective in women with HIV, and these may be used without restriction in women who are clinically well and on antiretroviral therapy (category 1). Although IUDs are still considered reasonable options in women with HIV who are not clinically well or not on antiretroviral therapy, the U.S. MEC ranks initiation of IUDs as category 2 and continuation of IUDs previously inserted as category 1. The use of IUDs in women has not been associated with increased HIV disease progression, risk of HIV transmission, or genital viral shedding. In addition, there is no evidence to suggest increased risks of infectious complications, such as pelvic inflammatory disease (PID), associated with IUD use in women with HIV.[38,40] There are multiple intrauterine devices used for contraception.

Table 1.

### Intrauterine Devices Used for Contraception

| Device  |                        |            |          | Component in IUD | Pregnancy Rate Year 1* | Approved Duration^ |
|---|------------------------|------------|----------|------------------|------------------------|--------------------|
| <b>Non-Hormonal Copper IUD</b>  |                        |            |          |                  |                        |                    |
| <i>ParaGard</i>   | Copper coil            | 0.60-0.80% | 10 years |                  |                        |                    |
| <b>Levonorgestrel-Releasing IUDs</b>  |                        |            |          |                  |                        |                    |
| <i>Mirena</i>   | 52 mg levonorgestrel   | 0.20%      | 5 years  |                  |                        |                    |
| <i>Liletta</i>  | 52 mg levonorgestrel   | 0.15%      | 6 years  |                  |                        |                    |
| <i>Kyleena</i>  | 19.5 mg levonorgestrel | 0.16%      | 5 years  |                  |                        |                    |
| <i>Skyla</i>  | 13.5 mg levonorgestrel | 0.41%      | 3 years  |                  |                        |                    |
| * These year 1 pregnancy rates are based on information provided in prescribing information     |                        |            |          |                  |                        |                    |
| ^ Approved Duration = United States Food and Drug Administration (FDA) approved duration of use |                        |            |          |                  |                        |                    |

Source:

- Curtis KM, Peipert JF. Long-Acting Reversible Contraception. N Engl J Med. 2017;376:461-468. [PubMed Abstract]

- **Condoms:** Women living with HIV using any contraceptive method other than condoms should

receive counseling regarding the use of condoms to reduce the risk of transmission of sexually transmitted infections and HIV, as well as to prevent pregnancy. This is particularly important for women with HIV on antiretroviral therapy regimens that may decrease the efficacy of their contraception method.

- **Spermicides:** The use of spermicides containing nonoxynol-9 should be avoided in women with or at risk for HIV due to concerns about this spermicide causing genital lesions, which could lead to the increased risk of HIV transmission and acquisition. Whether used alone, with condoms, or with a diaphragm, spermicides are rated category 3 (the risks of this method are thought to outweigh the benefits) in women with HIV.[\[38,41\]](#)

## Hormonal Contraception Interactions with Antiretroviral Medications

Since some antiretroviral medications and hormonal contraceptives are metabolized by the same enzyme pathways, drug interactions are a concern in women with HIV who are of childbearing age. The most common interactions between these classes of medications may cause compromised efficacy of the contraceptive method but, fortunately, rarely diminish the potency of the antiretroviral medications. In general, significant interactions with antiretroviral medications are more likely to occur with combined oral contraceptives and transdermal contraceptives compared with intrauterine devices (IUDs) and injectable DMPA.[\[36,38,42\]](#) Some of the most significant potential drug interactions between hormonal contraceptives and antiretroviral medications are highlighted below:[\[6,37,38\]](#)

- **Nucleoside Reverse Transcriptase Inhibitors (NRTIs):** There are no significant drug interactions expected between NRTIs and hormonal contraceptive methods.[\[43\]](#)
- **Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs):** Among the NNRTIs, efavirenz is the most likely to interact with hormonal contraceptives. Efavirenz is metabolized by the CYP3A4 enzyme pathway and may decrease blood levels of hormonal contraceptives, leading to decreased contraceptive efficacy, including the efficacy of emergency postcoital contraception.[\[44\]](#) The NNRTIs doravirine, etravirine, and rilpivirine do not have this effect.[\[38,44,45\]](#) There are no known significant interactions between NNRTIs and DMPA or levonorgestrel-releasing IUDs.[\[42\]](#)
- **Protease Inhibitors (PIs):** Protease inhibitors undergo metabolism via the same CYP3A4 enzyme pathway as many hormonal contraceptives and can alter hormone levels.[\[6\]](#) Although PIs generally inhibit CYP3A4 and would therefore be expected to increase hormone levels, most ritonavir-boosted PIs actually decrease levels of ethinyl estradiol and have unpredictable effects on progestins, norethindrone, and norgestimate, potentially decreasing contraceptive efficacy.[\[46\]](#) No significant interactions have been identified between protease inhibitors and injectable DMPA.[\[42,46\]](#) When women on hormonal contraceptives take protease inhibitors in the absence of a boosting agent, levels of the estrogen and progestin components of the contraceptive may increase.
- **Cobicistat:** Although relatively little is known about drug interactions between hormonal contraceptives and cobicistat, this pharmacologic booster is a potent inhibitor of CYP3A and CYP2D6 hepatic enzymes and theoretically could increase contraceptive hormone levels. In addition, the effect of cobicistat on hormonal contraceptives, when used with other antiretroviral medications, is not clearly understood, and theoretically, it may actually decrease hormone levels, similar to the effect caused by ritonavir-boosted protease inhibitors. The use of atazanavir-cobicistat with drospirenone-containing hormonal contraceptives is contraindicated due to potential hyperkalemia.[\[45\]](#) If darunavir-cobicistat is used with drospirenone-containing hormonal contraceptives, monitoring for hyperkalemia is recommended.[\[45\]](#)
- **Integrase Strand Transfer Inhibitors (INSTIs):** The INSTIs are not substrates for CYP enzymes and thus have lower potential for drug interactions with hormonal contraceptives. Bictegravir, cabotegravir, dolutegravir, and raltegravir have both been studied with combined oral contraceptive pills, and no significant drug interactions have been identified, and no dose adjustments are needed.[\[47,48\]](#) When elvitegravir is given in a fixed-dose combination with cobicistat, levels of ethinyl estradiol decrease, and levels of norgestimate increase significantly; consequently, clinicians should consider using an alternative hormonal contraceptive in women taking elvitegravir in combination with cobicistat. If these medications are taken together, individuals should be counseled about



possible increased risk of progestin side effects, including insulin resistance, dyslipidemia, acne, and venous thrombosis.[47,48]

- **CCR5 Co-Receptor Antagonists and Fusion Inhibitors:** There are no significant drug interactions expected between these antiretroviral therapies and hormonal contraceptive methods.[49]
- **Attachment Inhibitors:** Ethinyl estradiol dosing should not exceed 30 mcg daily when administered with fostemsavir, due to increased levels of the hormonal agent when combined with fostemsavir, potentially raising the risk for thromboembolic events.[50]

## Contraception Use and Risk of HIV Transmission

There are limited, high-quality data that address the potential impact of contraception on HIV transmission for women with HIV. The following summarizes the available data:

- A European study involving 563 HIV-serodifferent couples found no association between hormonal contraception and HIV transmission to the uninfected male partner.[51]
- A prospective cohort analysis in Africa that included 3,790 HIV-serodifferent couples (of which 2,476 had a female partner with HIV) found that women with HIV taking hormonal contraception (primarily injectable methods) had an approximately two-fold risk of transmitting HIV to their male partner compared with women who did not use hormonal contraception.[52] Women using injectable contraception had higher HIV levels in their endocervical secretions and this finding provided a plausible mechanism for the increased transmission risk.[52] In a multivariate analysis adjusted for age, pregnancy, unprotected sex, and plasma HIV RNA level, the investigators concluded that any hormonal contraceptive use by female partners with HIV increased the HIV acquisition risk in uninfected male partners, but the effect was statistically significant only for injectable contraceptives; the women in this study were not on antiretroviral therapy.[52]
- Several other studies have investigated the effect of hormonal contraception on HIV viral load set points, as well as cervical and vaginal HIV shedding; although some of these studies provide indirect evidence for a hormonally-mediated increase in infectivity (higher plasma RNA and higher rates of genital HIV shedding), the results have been mixed, with several studies showing no association or even an inverse association.[53,54]
- A recent systematic review of women living with HIV and using IUDs (either levonorgestrel- or copper-containing) found no difference in disease progression or genital viral shedding compared with women using other forms of contraception.[55]

## Effect of Hormonal Contraception on HIV Disease Progression

Data on the impact of hormonal contraception on HIV disease progression are conflicting, as outlined below. It is important to note that most of the participants in clinical studies evaluating the effect of hormonal contraception on HIV progression were not taking antiretroviral therapy, so it remains unclear whether having a suppressed viral load on therapy would negate the potentially negative effects of hormonal contraception on HIV progression.[56]

- A study of 599 postpartum women with HIV in Zambia found that hormonal contraception was associated with more rapid disease progression, whereas the copper-containing IUD was safe and effective; secondary analysis of the data confirmed this relationship.[56,57]
- The same group studied 4,109 women at risk for HIV and found that neither implants/injectables nor oral contraceptive pills were associated with HIV disease progression.[57]
- A systematic review of 10 cohort studies and one randomized trial concluded that hormonal contraception is not associated with accelerated HIV disease progression; a variety of outcome measures were used to determine HIV progression, including mortality, onset of clinical AIDS, time to a CD4 cell count below 200 cells/mm<sup>3</sup>, CD4 count decline below a defined threshold, time to initiation of antiretroviral therapy, and increase in HIV RNA level.[58]
- A prospective study of 2,269 women with HIV similarly found no association between the use of



hormonal contraception and accelerated HIV disease progression, and another small study that specifically evaluated the levonorgestrel-releasing intrauterine device (LNG-IUD) also reported the LNG-IUD does not have any adverse impact on HIV progression.[[59](#),[60](#)]

## Contraception Considerations for Women at Risk for HIV

Health care providers should offer all women at risk of acquiring HIV counseling about reproductive goals and contraception options, and they should emphasize the importance of HIV prevention measures, including treatment as prevention strategies in partners with HIV, limiting the number of sex partners, the correct and consistent use of condoms, and availability of HIV PrEP and HIV PEP, regardless of the method of contraception chosen.

### Hormonal Contraception Use and Risk of HIV Acquisition

Systematic reviews of available data have concluded that no clear association exists between the use of non-injectable hormonal contraceptives, such as oral contraceptive pills, intrauterine devices, and implants, and the risk of HIV acquisition.[\[39,40,61,62\]](#) In contrast, several observational studies have suggested a possible increased risk of HIV acquisition with the use of the injectable progestin-only contraceptive DMPA.[\[52,63,64,65,66,67\]](#) Experts proposed several possible mechanisms for the observed increased risk of HIV acquisition associated with DMPA, including biologic changes (thinning of the vaginal epithelium or changes in vaginal flora), immune system changes (alteration in cytokines and antimicrobial peptides, increased inflammation, increased frequency of activated HIV target cells in the cervix, and changes in CCR5 expression), and behavioral factors (decreased condom use in the setting of reliable contraception).[\[39,65,68,69\]](#) Other studies, however, have contradicted concerns of DMPA and enhanced HIV risk acquisition, and several recent systematic reviews found no increased risk of HIV acquisition with the non-DMPA injectable progestin norethisterone enanthate (NET-EN).[\[63,70,71,72\]](#) The results of a randomized, open-label trial of intramuscular DMPA, copper IUDs, and levonorgestrel implants were published in 2019; this study, which enrolled approximately 7,800 women seronegative for HIV across multiple sites in 4 African countries, did not find any of these contraception methods to be associated with a higher rate of HIV acquisition.[\[73\]](#)

### U.S. MEC Guidance for Hormonal Contraception in Women at Risk for HIV

In April 2020, the CDC released an update to the U.S. MEC guidance pertaining to the use of hormonal contraception in women at high risk of acquiring HIV.[\[36,40\]](#) After a careful review of the current data and the updated World Health Organization (WHO) MEC guidance from 2019, the CDC decided to adopt the updated WHO guidance, which is summarized below and in the table.[\[40,74\]](#) Table 2.

#### Guidance for Contraceptive Use in Women at High Risk for HIV

| Copper-Containing IUD*  |              | LNG-IUD    |              |   |   | Implants |   | DMPA | POP | CHCs |
|---|--------------|------------|--------------|---|---|----------|---|------|-----|------|
| Initiation  | Continuation | Initiation | Continuation |   |   |          |   |      |     |      |
| 1   | 1            | 1          | 1            | 1 | 1 | 1        | 1 |      |     |      |
| <p><b>*Clarification with IUDs:</b> Many women at high risk for HIV are also at risk for other sexually transmitted diseases (STDs). For these women, refer to the recommendations in the “U.S. Medical Eligibility Criteria for Contraceptive Use” for women with other factors related to STDs and the “U.S. Selected Practice Recommendations for Contraceptive Use” on STD screening before IUD insertion.</p> <p><b>Evidence (IUDs):</b> High-quality evidence from one randomized clinical trial, along with low-quality evidence from two observational studies, suggested no increased risk for HIV acquisition with Cu-IUD use.§ No studies were identified for LNG-IUDs.¶</p> |              |            |              |   |   |          |   |      |     |      |

| Copper-Containing IUD* |              | LNG-IUD    |              | Implants | DMPA | POP | CHCs |
|------------------------|--------------|------------|--------------|----------|------|-----|------|
| Initiation             | Continuation | Initiation | Continuation |          |      |     |      |

**Evidence (implants, DMPA, POP):** High-quality evidence from one randomized clinical trial observed no statistically significant differences in HIV acquisition between DMPA-IM versus Cu-IUD, DMPA-IM versus LNG implant, and Cu-IUD versus LNG implant.¶,\*\* Of the low-to-moderate-quality evidence from 14 observational studies, some studies suggested a possible increased risk for HIV with progestin-only injectable use, which was most likely due to unmeasured confounding.¶ Low-quality evidence from 3 observational studies did not suggest an increased HIV risk for implant users.¶ No studies of sufficient quality were identified for POPs.¶

**Evidence (CHCs):** Low-to-moderate-quality evidence from 11 observational studies suggested no association between COC use (it was assumed that studies that did not specify oral contraceptive type examined mostly, if not exclusively, COC use) and HIV acquisition.¶ No studies of patch, ring, or combined injectable contraception were identified.¶

**Abbreviations:** IUD= intrauterine device; LNG-IUD = levonorgestrel-releasing intrauterine device; DMPA = depot medroxyprogesterone acetate (injectable); POP = progestin-only pill; CHC = combined hormonal contraceptive

\*Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-3).

†Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-4).

§ Hannaford PC, Ti A, Chipato T, Curtis KM. Copper intrauterine device use and HIV acquisition in women: a systematic review. BMJ Sex Reprod Health. 2020;46:17–25.¶ Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN. Hormonal contraception and HIV acquisition among women: an updated systematic review. BMJ Sex Reprod Health 2020;46:8–16.

\*\* Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomized, multicentre, open-label trial. Lancet 2019;394:303–13.

### Summary of Categories for classifying contraceptives

1 = A condition for which there is no restriction for the use of the contraceptive method.

| Copper-Containing IUD*  |              | LNG-IUD    |              | Implants |  | DMPA | POP | CHCs |
|---|--------------|------------|--------------|----------|--|------|-----|------|
| Initiation  | Continuation | Initiation | Continuation |          |  |      |     |      |
| <p>2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.</p> <p>3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.</p> <p>4 = A condition that represents an unacceptable health risk if the contraceptive method is used.</p> |              |            |              |          |  |      |     |      |

Source:

- Tepper NK, Curtis KM, Cox S, Whiteman MK. Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection. MMWR Morb Mortal Wkly Rep. 2020;69:405-10. [[PubMed Abstract](#)]
- All hormonal contraceptive options should be available to women at high risk of acquiring HIV.
- Despite conflicting data about an increased risk of HIV acquisition in women using progestin-only injectable contraception (including DMPA), the advantages of these methods outweigh theoretical or proven risks, and progestin-only injectable contraception may be initiated or continued without restriction in women at high risk for HIV without restriction (category 1).
- Women considering progestin-only injectable contraception should be counseled about the concerns of increased risk of HIV acquisition in women while using this method, the unclear causal relationship, and strategies to minimize the risk of HIV infection.
- There are no restrictions for the use of other hormonal contraceptive methods (including combined hormonal methods, implants, and progestin-only pills) in women at high risk of acquiring HIV (category 1).
- IUD use (both initiation and continuation) is rated category 1 in women at risk for HIV.
- Finally, spermicides containing nonoxynol-9 should not be used in women with or at risk of acquiring HIV due to concerns about this spermicide causing genital lesions, which could lead to increased risk of transmission and acquisition of HIV. Whether used alone, with condoms, or with a diaphragm, spermicides are rated category 4 (unacceptable health risk) in women at risk of acquiring HIV.

# Serodifferent Couples Desiring Pregnancy

## General Recommendations

Serodifferent couples who wish to conceive a child should first ensure the partner with HIV achieves sustained virologic suppression (two plasma HIV RNA levels below the limit of detection at least 3 months apart).[\[37\]](#) Once sustained virologic suppression has been achieved in the person with HIV, the serodifferent couple can have condomless sexual intercourse in attempts for conception with effectively no risk of HIV transmission.[\[37\]](#) Both partners should undergo screening and treatment for sexually transmitted infections prior to attempting conception.[\[37\]](#) Several studies, as highlighted below, have shown a lack of HIV transmission in serodifferent couples if the partners with HIV were taking antiretroviral therapy and had stably suppressed HIV RNA levels.[\[37\]](#)

- **HPTN 052:** The HPTN-052 trial was a randomized, controlled study that enrolled 1,763 HIV serodifferent, predominantly heterosexual couples from 9 countries.[\[75,76\]](#) All persons with HIV had a CD4 count of 350 to 550 cells/mm<sup>3</sup> at enrollment, and none had HIV-related symptoms.[\[75,76\]](#) All new HIV infections were analyzed phylogenetically, and during the trial no linked HIV infections occurred between partners when the partner with HIV was taking antiretroviral therapy and had stably suppressed HIV RNA levels.[\[75,76\]](#)
- **Partner-1 Study:** In the first phase of the European PARTNER (Partners of People on ART—A New Evaluation of the Risks) study, investigators at 75 sites in 14 European countries evaluated the impact of antiretroviral therapy on HIV transmission risk in 888 HIV-serodifferent couples engaging in condomless sex, including 548 heterosexual couples. The eligibility for enrollment required the partner with HIV to be taking antiretroviral therapy and have an HIV RNA level of less than 200 copies/mL. During the trial, there were zero phylogenetically linked HIV transmissions that occurred in these couples, with an estimated 58,000 condomless sex acts, including an estimated 36,000 in heterosexual couples. There were 11 new HIV infections during the study period, but none of these were phylogenetically linked.
- **Natural Conception Study:** In this prospective study, investigators evaluated the risk of HIV transmission among 161 HIV-serodifferent couples who were attempting conception.[\[77\]](#) Enrollment required the partner with HIV to have received suppressive antiretroviral therapy for at least 6 months prior to entering the study.[\[77\]](#) Among the 161 serodifferent couples enrolled, 133 (83%) had a male partner with HIV, and 28 (17%) had a female partner with HIV.[\[77\]](#) During the study, there were a total of 144 natural pregnancies, 107 babies born, and no cases of sexual HIV transmission occurred.[\[77\]](#)

## Female Partner with HIV

When an HIV-serodifferent couple wishes to conceive and the female partner has HIV, the main prevention strategy is to have the woman achieve virologic suppression—defined as two plasma HIV RNA measurements below the limit of detection—before attempting conception.[\[37\]](#) Another option is to have the man take HIV PrEP (as outlined below). In addition, the risk of female-to-male HIV transmission can be eliminated, regardless of the woman's HIV RNA level, if the couple utilizes impregnation techniques without having condomless intercourse.[\[37\]](#) A common impregnation method is to perform periovulatory artificial insemination, either by self-insemination with the partner's semen, such as with a plastic (needleless) syringe, or with the assistance of a medical professional using intrauterine insemination.[\[37\]](#) In vitro fertilization is considered another very safe option, but it is cost-prohibitive for many couples and not usually necessary unless fertility problems exist. If the couple changes their plan and elects to try to conceive via unprotected sexual intercourse, they should be advised only to proceed after the woman has attained suppressed plasma HIV RNA levels on antiretroviral therapy for at least 3 months.[\[37\]](#)

## Male Partner with HIV

When an HIV-serodifferent couple wishes to conceive and the male partner has HIV, the main prevention strategy is to have the man achieve sustained virologic suppression—defined as two plasma HIV RNA measurements below the limits of detection at least 3 months apart—before attempting conception.[\[37\]](#) Another option is to have the woman take HIV PrEP (as outlined below). Additional options to consider include using donated sperm from another man who does not have HIV, or the use of sperm preparation techniques (e.g., sperm washing), coupled with either intrauterine insemination or in vitro fertilization with intracytoplasmic sperm injection.[\[37\]](#) Unfortunately, many of the assisted reproductive technology services, such as using donor sperm or surrogacy, while viable options for conception, may not be feasible due to prohibitive costs or lack of access to sperm washing. Given the extraordinary effectiveness of antiretroviral therapy in preventing sexual HIV transmission, the importance of sperm washing and other reproductive technology methods in HIV-serodifferent couples has diminished. If the female partner of a man living with HIV becomes pregnant, she should undergo HIV testing and close monitoring during the pregnancy.

## **Periconception HIV Preexposure Prophylaxis (PrEP)**

In certain circumstances, the use of HIV PrEP in HIV-serodifferent couples may be warranted in couples attempting conception.[\[37,78,79\]](#) Limited data exist regarding the efficacy and optimal use of HIV PrEP in HIV-serodifferent couples planning pregnancy. The use of HIV PrEP would be appropriate for the HIV-seronegative person in the HIV-serodifferent couple attempting conception if any of the following exist: the partner with HIV had not achieved suppressed HIV RNA levels for at least 3 months, the partner's plasma HIV RNA level is not known, there are concerns about the partner's adherence with antiretroviral therapy during the periconception period, and/or the HIV seronegative partner prefers to take HIV PrEP.[\[37\]](#) There are some data regarding pregnancy outcomes for women receiving tenofovir DF-emtricitabine-containing HIV PrEP who become pregnant. In several large randomized HIV PrEP trials, tenofovir DF-emtricitabine HIV PrEP regimens were promptly stopped if the woman in the trial became pregnant.[\[80,81\]](#) A subanalysis of the data from the Partners PrEP Study (conducted at multiple sites in Kenya and Uganda) showed no significant differences in pregnancy incidence, birth outcomes, or infant growth among women who were taking tenofovir DF-emtricitabine-containing HIV PrEP at the time of conception.[\[80,81\]](#) If periconception HIV PrEP is used as the primary prevention strategy, the partner without HIV should initiate HIV PrEP one month before conception is attempted and continue for as long as indicated.[\[82,83,84\]](#) The use of tenofovir alafenamide-emtricitabine is not recommended for HIV PrEP to prevent vaginal acquisition of HIV, and there are inadequate data on the use of cabotegravir in pregnancy.

# Vaginitis in Women with HIV

Although most women will experience at least one episode of vaginitis in their lifetime, women with HIV develop vaginal infections more commonly than women without HIV.<sup>[85]</sup> These infections can influence susceptibility to sexually transmitted infections and increase the risk of HIV transmission to partners who do not have HIV. Three of the most common vaginal infections that occur in women with HIV are addressed in this section: bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis. A more comprehensive discussion of female genitourinary infections, including sexually transmitted infections, is available in the 2021 STI Treatment Guidelines.<sup>[85]</sup>

## Bacterial Vaginosis

Bacterial vaginosis is a condition in which the predominant vaginal hydrogen peroxide-producing *Lactobacillus* species are overgrown with abundant anaerobic bacteria. Women with bacterial vaginosis may be asymptomatic, or they may develop vaginal discharge with a characteristic fishy (amine) odor. Bacterial vaginosis tends to occur (and recur) more frequently in women with HIV infection compared with women who do not have HIV; bacterial vaginosis increases the risk of acquiring other sexually transmitted diseases, and it can also increase the risk of HIV transmission to partners without HIV.<sup>[86,87,88]</sup>

- **Diagnosis:** The gold standard for diagnosing bacterial vaginosis is a Gram’s stain of the vaginal discharge, which reveals a low concentration of lactobacilli, with multiple gram-negative and gram-variable rods and cocci. In clinical practice, however, the Amsel criteria, point-of-care assays, and nucleic acid amplification tests (NAATs) are now more often used to diagnose bacterial vaginosis. The Amsel Diagnostic Criteria requires three of the following are met: (1) homogenous thin discharge coating the vaginal walls, (2) vaginal epithelial cells studded with adherent coccobacilli on microscopy (clue cells), (3) vaginal pH greater than 4.5, and (4) a fishy (amine) odor to the vaginal discharge that occurs when adding 10% potassium hydroxide (positive whiff test).<sup>[88]</sup> The recommended point-of-care assays include the OSOM BVBlue test, Affirm VPIII, and FemExam Test Card.<sup>[88]</sup> Recommended NAATs include the BD MAX Vaginal Panel (real-time polymerase chain reaction [PCR] assay) and the Aptima BV Test.<sup>[88]</sup>
- **Treatment:** The treatment of bacterial vaginosis for women with HIV is the same as for women without HIV. There are three recommended treatment options for the treatment of bacterial vaginosis in nonpregnant women: (1) metronidazole 500 mg orally twice daily for 7 days, (2) metronidazole gel 0.75% applied in one full applicator (5 g) intravaginally once a day for 5 days, or (3) clindamycin cream 2% applied in one full applicator (5 g) intravaginally at bedtime for 7 days.<sup>[88]</sup> Alternative regimens include the use of oral clindamycin, intravaginal clindamycin ovules, oral secnidazole, and oral tinidazole.<sup>[88,89,90]</sup> A recently published study showed that treatment of male sex partners of women diagnosed with markedly reduces the incidence of recurrent bacterial vaginosis in women; in this trial, the male sex partners were treated with oral metronidazole and topical clindamycin cream (applied to penis glans and upper shaft).<sup>[91]</sup>

### 2021 STI Treatment Guidelines: Bacterial Vaginosis

#### Table 3. Treatment of Bacterial Vaginosis

Recommended **Regimens**

Metronidazole



## **Metronidazole**

Tradename: Flagyl

500 mg orally twice a day for 7 days

### Recommended **Regimens**

Metronidazole gel 0.75%

## **Metronidazole gel 0.75%**

Tradename:

one full applicator (5 g) intravaginally, once a day for 5 days

### Recommended **Regimens**

Clindamycin vaginal cream 2%

## **Clindamycin vaginal cream 2%**

Tradename: Cleocin vaginal cream

one full applicator (5 g) intravaginally at bedtime for 7 days

Note: Clindamycin cream is oil based and might weaken latex condoms and diaphragms for 5 days after use.

### Alternative **Regimens**

Clindamycin

## **Clindamycin**

Tradename: Cleocin

300 mg orally twice daily for 7 days

#### Alternative **Regimens**

Clindamycin ovules

### **Clindamycin ovules**

Tradename:

100 mg intravaginally once at bedtime for 3 days

Note: Clindamycin ovules use an oleaginous base that might weaken latex or rubber products (e.g. condoms and diaphragms). Use of such products within 72 hours after treatment with clindamycin ovules is not recommended.

#### Alternative **Regimens**

Secnidazole

### **Secnidazole**

Tradename: Solosec

2 g oral granules in a single dose

Note: Oral granules should be sprinkled onto unsweetened applesauce, yogurt, or pudding before ingestion. A glass of water can be taken after administration to aid in swallowing.

#### Alternative **Regimens**

Tinidazole

### **Tinidazole**

Tradename:Tindamax

2 g orally once daily for 2 days

### Alternative **Regimens**

Tinidazole

## **Tinidazole**

Tradename:Tindamax

1 g orally once daily for 5 days

Source: Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Diseases characterized by vaginal itching, burning, irritation, odor or discharge: bacterial vaginosis. MMWR Recomm Rep. 2021;70(No. RR-4):1-187. [[2021 STI Treatment Guidelines](#)]

Courtesy of [National STD Curriculum](#).

## **Trichomoniasis**

Trichomoniasis is a common sexually transmitted infection in the United States caused by a protozoan pathogen, *Trichomonas vaginalis*, and some studies have found that more than half of women with HIV are coinfecting with *T. vaginalis* at some point in their lives.[[92](#)] In women living with HIV, *T. vaginalis* infection increases the risk of pelvic inflammatory disease, and it increases the shedding of HIV from the genital tract, which may increase the risk of HIV transmission.[[92](#)] Among sexually active women without HIV, *T. vaginalis* infection is also an independent risk factor for acquiring HIV.[[92](#)] A randomized clinical trial found that single-dose therapy with metronidazole 2 g orally was less effective than the 7-day metronidazole regimen for women with HIV and trichomoniasis: follow-up positive trichomonas tests were higher in the group receiving single dose metronidazole.([Figure 3](#)).[[93](#)]

- **Diagnosis:** Women with trichomoniasis may present with malodorous, yellow-green vaginal discharge, vulvar irritation, or they may be asymptomatic. The use of nucleic acid amplification testing (NAAT) in vaginal, endocervical, or urine specimens has become the gold standard for diagnosing trichomoniasis in women, replacing the wet mount preparation and culture for this purpose when available.[[92](#)]
- **Treatment:** The preferred treatment option for trichomoniasis in women with HIV is metronidazole 500 mg orally twice daily for 7 days; the alternative treatment for women is tinidazole 2 g orally in a single dose.[[92](#)]

## **2021 STI Treatment Guidelines: Trichomoniasis**

### **Table 4. Treatment of Trichomoniasis**

#### Recommended **Regimen for Women**

Metronidazole

#### **Metronidazole**

Tradename:Flagyl

500 mg orally twice a day for 7 days

#### Recommended **Regimen for Men**

Metronidazole

#### **Metronidazole**

Tradename:Flagyl

2 g orally in a single dose

#### Alternative **Regimen for Women and Men**

Tinidazole

#### **Tinidazole**

Tradename:Tindamax

2 g orally in a single dose

Source: Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Diseases characterized by vaginal itching, burning, irritation, odor or discharge: trichomoniasis. MMWR Recomm Rep. 2021;70(No. RR-4):1-187. [[2021 STI Treatment Guidelines](#)]

Courtesy of [National STD Curriculum](#).

## Vulvovaginal Candidiasis

Vulvovaginal candidiasis is a common problem among women with HIV, occurring more frequently in this population than in women without HIV.[[94,95](#)] Recurrent vulvovaginal candidiasis may be the initial clinical presentation in women with HIV; with more advanced HIV disease, vulvovaginal candidiasis is often more severe and may recur more frequently.[[94,96](#)] Vulvovaginal candidiasis can impact the vaginal epithelium and increase susceptibility to sexually transmitted infections, including HIV. In addition, women with HIV and vulvovaginal candidiasis have higher concentrations of HIV in genital fluids; it is not clear, however, if treatment of vulvovaginal candidiasis alters the risk of HIV acquisition or transmission.[[94](#)]

- **Diagnosis:** Women with early stages of HIV usually have manifestations of vulvovaginal candidiasis that are similar to women without HIV, namely mucosal burning and itching with evidence of white adherent plaques.[[96](#)] The diagnosis is confirmed by examining a wet mount of vaginal secretions and finding hyphal forms after applying 10% potassium hydroxide (KOH).[[94](#)] In the absence of other causes of vaginitis, such as bacterial vaginosis or trichomoniasis, a woman with candida infection should have a normal vaginal fluid pH (less than 4.5).[[94](#)] Vaginal fungal culture can be used to make a diagnosis in women with symptoms consistent with vulvovaginal candidiasis who have a negative wet mount.[[94](#)]
- **Treatment:** The preferred treatment options for vulvovaginal candidiasis in nonpregnant women consist of single-dose fluconazole 150 mg orally or short-course topical azoles.[[94,96](#)] Topical antifungal therapy should be used instead of fluconazole to treat vulvovaginal candidiasis in pregnant women with HIV.[[96](#)] If topical therapies are chosen, it is especially important to counsel women with HIV that the available creams and suppositories are oil-based and might weaken latex condoms. For women with frequent or severe recurrences of vulvovaginal candidiasis, some experts recommend using a long treatment course (e.g., oral fluconazole 100 mg, 150 mg, or 200 mg orally every third day for a total of 3 doses), followed by a maintenance regimen of fluconazole 100 mg, 150 mg, or 200 mg weekly for 6 months.[[94](#)]

## 2021 STI Treatment Guidelines: Vulvovaginal Candidiasis

### Table 5. Treatment of Uncomplicated Vulvovaginal Candidiasis

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Clotrimazole 1% cream

#### Clotrimazole 1% cream

Tradename:

5 g intravaginally daily for 7–14 days

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Clotrimazole 2% cream

### **Clotrimazole 2% cream**

Tradename:

5 g intravaginally daily for 3 days

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Miconazole 2% cream

### **Miconazole 2% cream**

Tradename: Monistat

5 g intravaginally daily for 7 days

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Miconazole 4% cream

### **Miconazole 4% cream**

Tradename:

5 g intravaginally daily for 3 days

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Miconazole 100 mg vaginal suppository

## **Miconazole 100 mg vaginal suppository**

Tradename: Monistat 7

one suppository daily for 7 days

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Miconazole 200 mg vaginal suppository

## **Miconazole 200 mg vaginal suppository**

Tradename: Monistat 3

one suppository daily for 3 days

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Miconazole 1,200 mg vaginal suppository

## **Miconazole 1,200 mg vaginal suppository**

Tradename: Monistat 1

one suppository for 1 day

Recommended **Regimens: Over-the-Counter Intravaginal Agents**

Tioconazole 6.5% ointment

## **Tioconazole 6.5% ointment**

Tradename: Vagistat-1



5 g intravaginally in a single application

Recommended **Regimens: Prescription Intravaginal Agents**

Butoconazole 2% cream (single dose bioadhesive product)

### **Butoconazole 2% cream (single dose bioadhesive product)**

Tradename:Gynazole

5 g intravaginally in a single application

Recommended **Regimens: Prescription Intravaginal Agents**

Terconazole 0.4% cream

### **Terconazole 0.4% cream**

Tradename:Terazol 7

5 g intravaginally daily for 7 days

Recommended **Regimens: Prescription Intravaginal Agents**

Terconazole 0.8% cream

### **Terconazole 0.8% cream**

Tradename:Terazol 3

5 g intravaginally daily for 3 days

Recommended **Regimens: Prescription Intravaginal Agents**

Terconazole 80 mg vaginal suppository

## **Terconazole 80 mg vaginal suppository**

Tradename: Terazol 3 Suppository

one suppository daily for 3 days

Recommended **Regimen: Oral Agent**

Fluconazole

## **Fluconazole**

Tradename: Diflucan

150 mg orally in a single dose

Note: the creams and suppositories in these regimens are oil based and might weaken latex condoms and diaphragms. Patients should refer to condom product labeling for further information.

Source: Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Diseases characterized by vaginal itching, burning, irritation, odor or discharge: vulvovaginal candidiasis. MMWR Recomm Rep. 2021;70(No. RR-4):1-187. [[2021 STI Treatment Guidelines](#)]

Courtesy of [National STD Curriculum](#).

- **Prophylaxis:** Long-term prophylactic fluconazole in nonpregnant women can reduce colonization and recurrent symptoms of vulvovaginal candidiasis, but routine primary prophylaxis with fluconazole is not recommended in women living with HIV.[[94](#)]

## Intimate Partner Violence in Women with HIV

Intimate partner violence, defined as physical, sexual, or psychological abuse from a partner can impact the overall health of a woman with HIV. If a woman with HIV experiences intimate partner violence, this may place her at increased risk of developing mental health disorders.[\[97,98,99\]](#) Studies have found that 60 to 90% of women who are victims of intimate partner violence develop anxiety disorders, including post-traumatic stress disorder, and as many as 50% develop depression; these numbers are likely higher for women with HIV who already suffer higher rates of psychological disease at baseline.[\[100\]](#) Clinicians caring for women with HIV should screen for intimate partner violence, as well as screening for accompanying mental health symptoms, given that depression and post-traumatic stress disorder decrease quality of life and have been linked to poor adherence with antiretroviral therapy and subsequent treatment failure.[\[101,102\]](#)

## Menopause in Women with HIV

### Age at Menopause

With the widespread availability of effective antiretroviral therapy, women with HIV are living longer, and more are reaching menopause.[\[103,104\]](#) Available data suggest that menopause occurs at an earlier age in women with HIV than in the general population; however, the results are confounded by many other factors that affect age at menopause.[\[103,104,105\]](#) In one multivariate analysis of data collected from a prospective cohort of 667 women with HIV, the presence of a CD4 count less than 50 cells/mm<sup>3</sup> conferred a three-fold risk of early menopause.[\[103\]](#) Women with HIV also appear to experience a greater burden of menopausal symptoms compared with women without HIV.[\[105\]](#)

### Effect of Menopause on HIV Acquisition and Transmission

There are concerns that age-related vaginal epithelial changes (such as atrophy and decreased mucosal integrity) might enhance the risk for HIV acquisition and transmission, in much the same way that mucosal ulcers disrupt the mucosal barrier and can enhance HIV susceptibility and shedding.[\[106,107\]](#) Despite these concerns, postmenopausal women with HIV have not been found to have increased genital HIV shedding compared with younger women.[\[107\]](#)

### Antiretroviral Therapy in Peri- and Postmenopausal Women

Estrogen appears to have a protective effect on immune function, as evidenced by the fact that premenopausal women have higher CD4 counts and lower HIV RNA levels compared with age-matched men.[\[108\]](#) Despite concerns that postmenopausal women might have suboptimal immunologic and virologic responses to antiretroviral therapy as a result of decreasing estrogen levels, two studies have demonstrated equivalent responses to antiretroviral therapy regardless of menopausal status.[\[108\]](#) Unfortunately, given the higher rates of menopausal symptoms in women with HIV, there are limited data on the safety and efficacy of hormone replacement therapy in women with HIV, including limited information on drug interactions between hormonal therapies and antiretroviral medications.[\[105\]](#) Because current guidelines stress the need to weigh the risks and benefits of using hormone replacement therapy for the treatment of menopausal symptoms, women with HIV may not be ideal candidates for hormonal replacement therapy, given the increased rates of cardiovascular disease in the population living with HIV.[\[105,109\]](#)

### Impact of Menopause on Other Conditions

Earlier onset of menopause requires heightened vigilance for conditions that are associated with postmenopausal status, such as osteoporosis and cardiovascular disease, especially since HIV infection (and antiretroviral therapy, in some cases) may directly increase a woman's risk of developing these disorders.[\[103,104,105,110\]](#) There are no HIV-specific surveillance recommendations for these conditions in women with HIV, but clinicians should emphasize the importance of age-appropriate screening and counsel about secondary prevention measures, including smoking cessation and regular exercise.

## Summary Points

- In the United States, women and girls comprise an estimated 22% of all persons with HIV and approximately 19% of new HIV infections.
- Among women and girls in the United States with HIV, the identified factor for acquiring HIV was heterosexual contact in 80% and injection drug use in 20%.
- Black/African American and Latina women have disproportionately higher HIV prevalence and incidence rates.
- Women and men have similar virologic responses to antiretroviral therapy, though women are more likely to experience an increase in some antiretroviral-related adverse effects, such as loss in bone mineral density with tenofovir DF and ritonavir-boosted protease inhibitors.
- For women with HIV who may become pregnant, the antiretroviral regimen should take into consideration what regimens are recommended for use during pregnancy.
- Women living with HIV should be offered the full array of contraceptive options and counseled about potential drug interactions with antiretroviral therapy.
- Multiple options exist for serodifferent couples seeking pregnancy. The strategies should be individualized, and the approach may differ based on which partner is living with HIV. The use of HIV PrEP has expanded these options.
- Women with HIV experience vaginal infections more often than women without HIV, and these infections can influence susceptibility to sexually transmitted infections and increase the risk of HIV transmission to uninfected partners.
- Menopause may be earlier and more symptomatic in women with HIV compared to women without HIV, but there is no data to support a link between menopause-related vaginal mucosal changes and an increased risk of HIV transmission to others.
- Women with HIV experience high rates of intimate partner violence and should be screened for this as part of their comprehensive care.

## Citations

1. UNAIDS/AIDSinfo. HIV and AIDS estimates: global factsheets 2017.  
[[UN AIDS/AIDSinfo](#)] -
2. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2018 (Updated). HIV Surveillance Report, 2020; vol. 31:1-119. Published May 2020.  
[[CDC](#)] -
3. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2014–2018. HIV Surveillance Supplemental Report. 2020;25(No. 1):1-77. Published May 2020.  
[[CDC](#)] -
4. Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2017–2021. HIV Surveillance Supplemental Report. 2023;28(3). Published May 2023.  
[[CDC](#)] -
5. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas, 2021. HIV Surveillance Report, 2021; vol. 34. Published May 2023.  
[[CDC](#)] -
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Considerations for antiretroviral use in special patient populations: Women with HIV. September 12, 2024.  
[[HIV.gov](#)] -
7. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Initiation of antiretroviral therapy. December 18, 2019.  
[[HIV.gov](#)] -
8. Currier J, Averitt Bridge D, Hagins D, et al. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010;153:349-57.  
[[PubMed Abstract](#)] -
9. Collazos J, Asensi V, Cartón JA. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART. AIDS. 2007;21:835-43.  
[[PubMed Abstract](#)] -
10. Gandhi M, Aweeka F, Greenblatt RM, Blaschke TF. Sex differences in pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol. 2004;44:499-523.  
[[PubMed Abstract](#)] -
11. Ofotokun I, Chuck SK, Hitti JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gend Med. 2007;4:106-19.  
[[PubMed Abstract](#)] -
12. Venuto CS, Mollan K, Ma Q, et al. Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202. J Antimicrob Chemother. 2014;69:3300-10.  
[[PubMed Abstract](#)] -
13. Brown TT, Moser C, Currier JS, et al. Changes in Bone Mineral Density After Initiation of Antiretroviral

Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir. *J Infect Dis.* 2015;212:1241-9.

[\[PubMed Abstract\]](#) -

14. Grant PM, Kitch D, McComsey GA, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. *Clin Infect Dis.* 2013;57:1483-8.  
[\[PubMed Abstract\]](#) -
15. Sharma A, Shi Q, Hoover DR, et al. Increased Fracture Incidence in Middle-Aged HIV-Infected and HIV-Uninfected Women: Updated Results From the Women's Interagency HIV Study. *J Acquir Immune Defic Syndr.* 2015;70:54-61.  
[\[PubMed Abstract\]](#) -
16. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. *Osteoporos Int.* 2005;16:1345-52.  
[\[PubMed Abstract\]](#) -
17. Sax PE, Erlandson KM, Lake JE, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. *Clin Infect Dis.* 2020;71:1379-89.  
[\[PubMed Abstract\]](#) -
18. Kerchberger AM, Sheth AN, Angert CD, et al. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. *Clin Infect Dis.* 2020;71:593-600.  
[\[PubMed Abstract\]](#) -
19. Lake JE, Wu K, Bares SH, et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. *Clin Infect Dis.* 2020;71:e471-e477.  
[\[PubMed Abstract\]](#) -
20. Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. *Lancet HIV.* 2020;7:e666-e676.  
[\[PubMed Abstract\]](#) -
21. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. *Antepartum Care. Overview.* January 31, 2024.  
[\[HIV.gov\]](#) -
22. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. *Antepartum Care. Recommendations for Use of Antiretroviral Drugs During Pregnancy. Table 6. What to Start: Initial Antiretroviral Regimens During Pregnancy When Antiretroviral Therapy Has Never Been Received.* June 12, 2025.  
[\[HIV.gov\]](#) -
23. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. *Antepartum Care. Recommendations for Use of Antiretroviral Drugs During Pregnancy. Antiretroviral Therapy Use During Prepregnancy and Early Pregnancy.* June 12, 2025.  
[\[HIV.gov\]](#) -



24. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. What to Start. Initial Combination Antiretroviral Regimens for People With HIV. September 12, 2024.  
[[HIV.gov](#)] -
25. Zhang H, Hindman JT, Lin L, et al. A study of the pharmacokinetics, safety, and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed pregnant women with HIV. AIDS. 2024;38:F1-F9.  
[[PubMed Abstract](#)] -
26. Holt LM, Short WR, Momplaisir F, et al. Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating HIV Viral Suppression and Perinatal Outcomes. Clin Infect Dis. 2024;79:1258-61.  
[[PubMed Abstract](#)] -
27. Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med. 2018;379:979-81.  
[[PubMed Abstract](#)] -
28. Zash R, Holmes LB, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Abstract PEBLB14. Presented at: IAS; 2021. Virtual Conference  
[[PubMed Abstract](#)] -
29. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Recommendations for Use of Antiretroviral Drugs During Pregnancy. Teratogenicity. January 31, 2024.  
[[HIV.gov](#)] -
30. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Recommendations for Use of Antiretroviral Drugs During Pregnancy. Lack of Experience with Antiretroviral Drugs During Pregnancy and Prior to Pregnancy (Antiretroviral-Naive). June 12, 2025.  
[[HIV.gov](#)] -
31. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Appendix C: Antiretroviral Counseling Guide for Health Care Providers. June 12, 2025.  
[[HIV.gov](#)] -
32. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Antepartum Care. Recommendations for use of antiretroviral drugs during pregnancy. Recommendations for Use of Antiretroviral Drugs During Pregnancy. Table 7. Situation-Specific Recommendations for Use of Antiretroviral Drugs During Pregnancy and When Trying to Conceive. June 12, 2025.  
[[HIV.gov](#)] -
33. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Protease Inhibitors. Darunavir January 31, 2023.  
[[HIV.gov](#)] -

34. Stek A, Best BM, Wang J, et al. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women. *J Acquir Immune Defic Syndr*. 2015;70:33-41.  
[[PubMed Abstract](#)] -
35. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. *Lancet*. 2022;399:1779-89.  
[[PubMed Abstract](#)] -
36. Tepper NK, Curtis KM, Cox S, Whiteman MK. Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection. *MMWR Morb Mortal Wkly Rep*. 2020;69:405-10.  
[[PubMed Abstract](#)] -
37. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Preconception counseling and care for persons of childbearing age with HIV. Reproductive options when one or both partners have HIV. January 31, 2023.  
[[HIV.gov](#)] -
38. Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. *MMWR Recomm Rep*. 2016;65:1-103.  
[[MMWR](#)] -
39. Centers for Disease Control and Prevention (CDC). Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2010: revised recommendations for the use of hormonal contraception among women at high risk for HIV infection or infected with HIV. *MMWR Morb Mortal Wkly Rep*. 2012;61:449-52.  
[[PubMed Abstract](#)] -
40. Tepper NK, Krashin JW, Curtis KM, Cox S, Whiteman MK. Update to CDC's U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV Infection. *MMWR Morb Mortal Wkly Rep*. 2017;66:990-994.  
[[PubMed Abstract](#)] -
41. Wilkinson D, Ramjee G, Tholandi M, Rutherford G. Nonoxynol-9 for preventing vaginal acquisition of HIV infection by women from men. *Cochrane Database Syst Rev*. 2002;(4):CD003936.  
[[PubMed Abstract](#)] -
42. Tseng A, Hills-Niemenen C. Drug interactions between antiretrovirals and hormonal contraceptives. *Expert Opin Drug Metab Toxicol*. 2013;9:559-72.  
[[PubMed Abstract](#)] -
43. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Drug-drug interactions. Table 24c. Drug interactions between nucleoside reverse transcriptase inhibitors and other drugs (including antiretroviral agents). May 26, 2023.  
[[HIV.gov](#)] -
44. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Drug-drug interactions. Table 24b. Drug interactions between non-nucleoside reverse transcriptase inhibitors and other drugs. September 1, 2022

[\[HIV.gov\]](#) -

45. Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Preconception counseling and care for persons of childbearing age with HIV: overview. December 30, 2021.  
[\[HIV.gov\]](#) -
46. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Drug-drug interactions. Table 24a. Drug interactions between protease inhibitors and other drugs. September 1, 2022.  
[\[HIV.gov\]](#) -
47. Tittle V, Bull L, Boffito M, Nwokolo N. Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives. Clin Pharmacokinet. 2015;54:23-34.  
[\[PubMed Abstract\]](#) -
48. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Drug-drug interactions. Table 24d. Drug interactions between integrase strand transfer inhibitors and other drugs. September 12, 2024.  
[\[HIV.gov\]](#) -
49. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Drug-drug interactions. Table 24e. Drug interactions between the CCR5 antagonist maraviroc and other drugs (including antiretroviral agents). May 26, 2023.  
[\[HIV.gov\]](#) -
50. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Drug-drug interactions: drug interactions between HIV-1 gp120-directed attachment inhibitors and other drugs (including antiretroviral agents) June 3, 2021.  
[\[HIV.gov\]](#) -
51. Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV. BMJ. 1992;304:809-13.  
[\[PubMed Abstract\]](#) -
52. Heffron R, Donnell D, Rees H, et al. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect Dis. 2012;12:19-26.  
[\[PubMed Abstract\]](#) -
53. Blish CA, Baeten JM. Hormonal contraception and HIV-1 transmission. Am J Reprod Immunol. 2011;65:302-7.  
[\[PubMed Abstract\]](#) -
54. Polis CB, Phillips SJ, Curtis KM. Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS. 2013;27:493-505.  
[\[PubMed Abstract\]](#) -
55. Tepper NK, Curtis KM, Nanda K, Jamieson DJ. Safety of intrauterine devices among women with HIV: a systematic review. Contraception. 2016;94:713-724.

[\[PubMed Abstract\]](#) -

56. Stringer EM, Giganti M, Carter RJ, El-Sadr W, Abrams EJ, Stringer JS. Hormonal contraception and HIV disease progression: a multicountry cohort analysis of the MTCT-Plus Initiative. *AIDS*. 2009;23 Suppl 1:S69-77.  
[\[PubMed Abstract\]](#) -
57. Stringer EM, Levy J, Sinkala M, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. *AIDS*. 2009;23:1377-82.  
[\[PubMed Abstract\]](#) -
58. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. *AIDS*. 2013;27:787-94.  
[\[PubMed Abstract\]](#) -
59. Heffron R, Mugo N, Ngure K, et al. Hormonal contraceptive use and risk of HIV-1 disease progression. *AIDS*. 2013;27:261-7.  
[\[PubMed Abstract\]](#) -
60. Heikinheimo O, Lehtovirta P, Aho I, Ristola M, Paavonen J. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. *AJOG*. 2011;204(2):126.e1-4.  
[\[PubMed Abstract\]](#) -
61. Ralph LJ, McCoy SI, Shiu K, Padian NS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. *Lancet Infect Dis*. 2015;15:181-9.  
[\[PubMed Abstract\]](#) -
62. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women: a systematic review of the epidemiological evidence. *Lancet Infect Dis*. 2013;13:797-808.  
[\[PubMed Abstract\]](#) -
63. Polis CB, Curtis KM, Hannaford PC, et al. An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. *AIDS*. 2016;30:2665-2683.  
[\[PubMed Abstract\]](#) -
64. Noguchi LM, Richardson BA, Baeten JM, et al. Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. *Lancet HIV*. 2015;2:e279-87.  
[\[PubMed Abstract\]](#) -
65. Delvaux T, Buvé A. Hormonal contraception and HIV acquisition - what is the evidence? What are the policy and operational implications? *Eur J Contracept Reprod Health Care*. 2013;18:15-26.  
[\[PubMed Abstract\]](#) -
66. Colvin CJ, Harrison A. Broadening the debate over HIV and hormonal contraception. *Lancet Infect Dis*. 2015;15:135-6.  
[\[PubMed Abstract\]](#) -
67. McCoy SI, Zheng W, Montgomery ET, et al. Oral and injectable contraception use and risk of HIV acquisition among women in sub-Saharan Africa. *AIDS*. 2013;27:1001-9.  
[\[PubMed Abstract\]](#) -
68. Ramjee G, McCormack S. The role of progestins in HIV acquisition in young women. *Lancet Infect Dis*.

2016;16:389-90.

[\[PubMed Abstract\]](#) -

69. Byrne EH, Anahtar MN, Cohen KE, et al. Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. *Lancet Infect Dis.* 2016;16:441-8.  
[\[PubMed Abstract\]](#) -
70. Kleinschmidt I, Rees H, Delany S, et al. Injectable progestin contraceptive use and risk of HIV infection in a South African family planning cohort. *Contraception.* 2007;75:461-7.  
[\[PubMed Abstract\]](#) -
71. Morrison CS, Chen PL, Kwok C, et al. Hormonal contraception and the risk of HIV acquisition: an individual participant data meta-analysis. *PLoS Med.* 2015;12:e1001778.  
[\[PubMed Abstract\]](#) -
72. Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. *AIDS.* 2007;21:85-95.  
[\[PubMed Abstract\]](#) -
73. Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trial. *Lancet.* 2019;394:303-13.  
[\[PubMed Abstract\]](#) -
74. World Health Organization. Contraceptive eligibility for women at high risk of HIV: guidance statement: recommendations on contraceptive methods used by women at high risk of HIV. Geneva, Switzerland: World Health Organization; 2019.  
[\[WHO\]](#) -
75. Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med.* 2016;375:830-9.  
[\[PubMed Abstract\]](#) -
76. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med.* 2011;365:493-505.  
[\[PubMed Abstract\]](#) -
77. Del Romero J, Baza MB, Río I, et al. Natural conception in HIV-serodiscordant couples with the infected partner in suppressive antiretroviral therapy: A prospective cohort study. *Medicine (Baltimore).* 2016;95:e4398.  
[\[PubMed Abstract\]](#) -
78. Heffron R, Pintye J, Matthews LT, Weber S, Mugo N. PrEP as Peri-conception HIV Prevention for Women and Men. *Curr HIV/AIDS Rep.* 2016;13:131-9.  
[\[PubMed Abstract\]](#) -
79. Vernazza PL, Graf I, Sonnenberg-Schwan U, Geit M, Meurer A. Preexposure prophylaxis and timed intercourse for HIV-discordant couples willing to conceive a child. *AIDS.* 2011;25:2005-8.  
[\[PubMed Abstract\]](#) -
80. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. *N Engl J Med.* 2012;367:399-410.

[\[PubMed Abstract\]](#) -

81. Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312:362-71.  
[\[PubMed Abstract\]](#) -
82. US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update. Clinical providers' supplement. March 2018:1-59.  
[\[CDC\]](#) -
83. Bazzi AR, Leech AA, Biancarelli DL, Sullivan M, Drainoni ML. Experiences Using Pre-Exposure Prophylaxis for Safer Conception Among HIV Serodiscordant Heterosexual Couples in the United States. AIDS Patient Care STDS. 2017;31:348-355.  
[\[PubMed Abstract\]](#) -
84. Seidman DL, Weber S, Timoney MT, et al. Use of HIV pre-exposure prophylaxis during the preconception, antepartum and postpartum periods at two United States medical centers. Am J Obstet Gynecol. 2016;215:632.e1-632.e7.  
[\[PubMed Abstract\]](#) -
85. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Diseases characterized by vaginal itching, burning, irritation, odor or discharge. MMWR Recomm Rep. 2021;70(No. RR-4):1-187.  
[\[2021 STI Treatment Guidelines\]](#) -
86. Cohen CR, Lingappa JR, Baeten JM, et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 2012;9:e1001251.  
[\[PubMed Abstract\]](#) -
87. Jamieson DJ, Duerr A, Klein RS, et al. Longitudinal analysis of bacterial vaginosis: findings from the HIV epidemiology research study. Obstet Gynecol. 2001;98:656-63.  
[\[PubMed Abstract\]](#) -
88. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Diseases characterized by vaginal itching, burning, irritation, odor or discharge: bacterial vaginosis. MMWR Recomm Rep. 2021;70(No. RR-4):1-187.  
[\[2021 STI Treatment Guidelines\]](#) -
89. Hillier SL, Nyirjesy P, Waldbaum AS, et al. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial. Obstet Gynecol. 2017;130:379-386.  
[\[PubMed Abstract\]](#) -
90. Schwebke JR, Morgan FG Jr, Koltun W, Nyirjesy P. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis. Am J Obstet Gynecol. 2017;217:678.e1-678.e9.  
[\[PubMed Abstract\]](#) -
91. Vodstrcil LA, Plummer EL, Fairley CK, et al. Male-Partner Treatment to Prevent Recurrence of Bacterial Vaginosis. N Engl J Med. 2025;392:947-57.  
[\[PubMed Abstract\]](#) -
92. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Diseases characterized by vaginal itching, burning, irritation, odor or discharge: trichomoniasis.

MMWR Recomm Rep. 2021;70(No. RR-4):1-187.

[\[2021 STI Treatment Guidelines\]](#) -

93. Kissinger P, Mena L, Levison J, et al. A randomized trial: a single versus 7-day dose of metronidazole for the treatment of *Trichomonas vaginalis* among HIV-infected women. *J Acquir Immune Defic Syndr*. 2010;55:565-71.  
[\[PubMed Abstract\]](#) -
94. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. Diseases characterized by vaginal itching, burning, irritation, odor or discharge: vulvovaginal candidiasis. *MMWR Recomm Rep*. 2021;70(No. RR-4):1-187.  
[\[2021 STI Treatment Guidelines\]](#) -
95. Duerr A, Heilig CM, Meikle SF, et al. Incident and persistent vulvovaginal candidiasis among human immunodeficiency virus-infected women: Risk factors and severity. *Obstet Gynecol*. 2003;101:548-56.  
[\[PubMed Abstract\]](#) -
96. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Candidiasis (mucocutaneous). September 16, 2024.  
[\[HIV.gov\]](#) -
97. Zunner B, Dworkin SL, Neylan TC, et al. HIV, violence and women: unmet mental health care needs. *J Affect Disord*. 2014;174:619-26.  
[\[PubMed Abstract\]](#) -
98. Orza L, Bewley S, Chung C, et al. "Violence. Enough already": findings from a global participatory survey among women living with HIV. *J Int AIDS Soc*. 2015;18:20285.  
[\[PubMed Abstract\]](#) -
99. Maman S, Campbell J, Sweat MD, Gielen AC. The intersections of HIV and violence: directions for future research and interventions. *Soc Sci Med*. 2000;50:459-78.  
[\[PubMed Abstract\]](#) -
100. Were E, Curran K, Delany-Moretlwe S, et al. A prospective study of frequency and correlates of intimate partner violence among African heterosexual HIV serodiscordant couples. *AIDS*. 2011;25:2009-18.  
[\[PubMed Abstract\]](#) -
101. Blashill AJ, Perry N, Safren SA. Mental health: a focus on stress, coping, and mental illness as it relates to treatment retention, adherence, and other health outcomes. *Curr HIV/AIDS Rep*. 2011;8:215-22.  
[\[PubMed Abstract\]](#) -
102. Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. *J Acquir Immune Defic Syndr*. 2011;58:181-7.  
[\[PubMed Abstract\]](#) -
103. Calvet GA, Grinsztejn BG, Quintana Mde S, et al. Predictors of early menopause in HIV-infected women: a prospective cohort study. *Am J Obstet Gynecol*. 2015;212:765.e1-765.e13.  
[\[PubMed Abstract\]](#) -
104. Imai K, Sutton MY, Mdodo R, Del Rio C. HIV and Menopause: A Systematic Review of the Effects of HIV



Infection on Age at Menopause and the Effects of Menopause on Response to Antiretroviral Therapy. *Obstet Gynecol Int.* 2013;2013:340309.

[\[PubMed Abstract\]](#) -

105. Kanapathipillai R, Hickey M, Giles M. Human immunodeficiency virus and menopause. *Menopause.* 2013;20:983-90.

[\[PubMed Abstract\]](#) -

106. Kaul R, Pettengell C, Sheth PM, et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. *J Reprod Immunol.* 2008;77:32-40.

[\[PubMed Abstract\]](#) -

107. Melo KC, Melo MR, Ricci BV, Segurado AC. Correlates of human immunodeficiency virus cervicovaginal shedding among postmenopausal and fertile-aged women. *Menopause.* 2012;19:150-6.

[\[PubMed Abstract\]](#) -

108. Patterson KB, Cohn SE, Uyanik J, Hughes M, Smurzynski M, Eron JJ. Treatment responses in antiretroviral treatment-naïve premenopausal and postmenopausal HIV-1-infected women: an analysis from AIDS Clinical Trials Group Studies. *Clin Infect Dis.* 2009;49:473-6.

[\[PubMed Abstract\]](#) -

109. North American Menopause Society. The 2012 hormone therapy position statement of: The North American Menopause Society. *Menopause.* 2012;19:257-71.

[\[PubMed Abstract\]](#) -

110. Cortés YI, Yin MT, Reame NK. Bone Density and Fractures in HIV-infected Postmenopausal Women: A Systematic Review. *J Assoc Nurses AIDS Care.* 2015;26:387-98.

[\[PubMed Abstract\]](#) -

## References

- Achilles SL, Creinin MD, Stoner KA, Chen BA, Meyn L, Hillier SL. Changes in genital tract immune cell populations after initiation of intrauterine contraception. *Am J Obstet Gynecol.* 2014;211:489.e1-9. [\[PubMed Abstract\]](#) -
- Advisory Committee on Immunization Practices (ACIP). Recommended Immunization Schedule for Ages 19 Years or Older, United States, 2025. [\[ACIP\]](#) -
- Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. *J Acquir Immun Defic Syndr.* 2004;35:538-9. [\[PubMed Abstract\]](#) -
- Bohbot JM, Vicaute E, Fagnen D, Brauman M. Treatment of bacterial vaginosis: a multicenter, double-blind, double-dummy, randomised phase III study comparing secnidazole and metronidazole. *Infect Dis Obstet Gynecol.* 2010;2010. [\[PubMed Abstract\]](#) -
- Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. *AIDS.* 2006;20:2165-74. [\[PubMed Abstract\]](#) -
- Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and

dependent areas, 2018 (Preliminary). HIV Surveillance Report, 2019; vol. 30:1-129. Published November 2019.

[\[CDC\]](#) -

- Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2010–2016. HIV Surveillance Supplemental Report. 2019;24(No. 1):1-89. Published February 2019.  
[\[CDC\]](#) -
- Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data—United States and 6 Dependent Areas, 2021. HIV Surveillance Supplemental Report. 2023;28(No. 4). Published May 2023.  
[\[CDC\]](#) -
- Centers for Disease Control and Prevention. Rates of diagnoses of HIV infection among adults and adolescents, by area of residence, 2011—United States and 6 dependent areas. HIV Surveillance Report. 2011;vol 23:1-84. Published February 2013.  
[\[CDC\]](#) -
- Cohan D, Weber S, Goldschmidt R. Safer conception options for HIV-serodiscordant couples. Am J Obstet Gynecol. 2011;206:e21.  
[\[PubMed Abstract\]](#) -
- Curtis KM, Peipert JF. Long-Acting Reversible Contraception. N Engl J Med. 2017;376:461-468.  
[\[PubMed Abstract\]](#) -
- Department of Health and Human Services (HHS) Antiretroviral Guidelines Panels. HIV/AIDS News: Recommendations Regarding the Use of Dolutegravir in Adults and Adolescents with HIV who are Pregnant or of Child-Bearing Potential. May 30, 2018  
[\[AIDSinfo\]](#) -
- Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23:817-24.  
[\[PubMed Abstract\]](#) -
- Ford N, Calmy A, Mofenson L. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2011; 25: 2301-4.  
[\[PubMed Abstract\]](#) -
- Ford N, Mofenson L, Shubber Z, et al. Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS. 2014;28 Suppl 2:S123-31.  
[\[PubMed Abstract\]](#) -
- Friend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies: products in development. Antiviral Res. 2013;100 Suppl:S39-47.  
[\[PubMed Abstract\]](#) -
- Haddad LB, Feldacker C, Jamieson DJ, et al. Medical eligibility, contraceptive choice, and intrauterine device acceptance among HIV-infected women receiving antiretroviral therapy in Lilongwe, Malawi. Int J Gynaecol Obstet. 2014;126:213-6.  
[\[PubMed Abstract\]](#) -
- Heffron R, Mugo N, Were E, et al. Preexposure prophylaxis is efficacious for HIV-1 prevention among

women using depot medroxyprogesterone acetate for contraception. AIDS. 2014;28:2771-6.

[\[PubMed Abstract\]](#) -

- Hess KL, Hu X, Lansky A, Mermin J, Hall HI. Lifetime risk of a diagnosis of HIV infection in the United States. Ann Epidemiol. 2017;27:238-243.  
[\[PubMed Abstract\]](#) -
- Lampe MA, Smith DK, Anderson GJE, Edwards AE, Nesheim SR. Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 2011;204:488.e1-8.  
[\[PubMed Abstract\]](#) -
- Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012;85:425-7.  
[\[PubMed Abstract\]](#) -
- Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet. 2021;397:1276-92.  
[\[PubMed Abstract\]](#) -
- Murnane PM, Heffron R, Ronald A, et al. Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception. AIDS. 2014;28:1825-30.  
[\[PubMed Abstract\]](#) -
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. Antiretroviral therapy to prevent sexual transmission of HIV (treatment as prevention). December 18, 2019.  
[\[HIV.gov\]](#) -
- Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the Use of Antiretroviral Drugs During Pregnancy and Interventions to Reduce Perinatal HIV Transmission in the United States. Antepartum care: recommendations for use of antiretroviral drugs during pregnancy. January 31, 2023.  
[\[HIV.gov\]](#) -
- Poonia B, Walter L, Dufour J, Harrison R, Marx PA, Veazey RS. Cyclic changes in the vaginal epithelium of normal rhesus macaques. J Endocrinol. 2006;190:829-35.  
[\[PubMed Abstract\]](#) -
- Rodger AJ, Cambiano V, Bruun T, et al. Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA. 2016;316:171-81.  
[\[PubMed Abstract\]](#) -
- Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. 2010;95:s1-s66.  
[\[PubMed Abstract\]](#) -
- Stellbrink HJ, Orkin C, Arribas JR, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the

ASSERT study. Clin Infect Dis. 2010;51:963-72.

[\[PubMed Abstract\]](#) -


- Stringer EM, Kaseba C, Levy J, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144.e1-8.  
[\[PubMed Abstract\]](#) -
- United States Census Bureau. Quick facts—United States.  
[\[United States Census Bureau\]](#) -
- US Census Bureau  
[\[US Census Bureau\]](#) -
- US Public Health Service. Preexposure prophylaxis for the prevention of HIV infection in the United States—2017 Update. A Clinical Practice Guideline. March 2018:1-77.  
[\[CDC\]](#) -
- Villegas G, Calenda G, Ugaonkar S, et al. A Novel Microbicide/Contraceptive Intravaginal Ring Protects Macaque Genital Mucosa against SHIV-RT Infection Ex Vivo. PLoS One. 2016;11:e0159332.  
[\[PubMed Abstract\]](#) -
- Williams PL, Yildirim C, Chadwick EG, et al. Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study. Lancet HIV. 2020;7:e49-e58.  
[\[PubMed Abstract\]](#) -
- Wolde-Yohannes S. Persisting failure to protect populations at risk from HIV transmission: African American women in the United States (US). J Public Health Policy. 2012;33:325-36.  
[\[PubMed Abstract\]](#) -
- Zash R, Holmes L, Diseko M, et al. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana. N Engl J Med. 2019;381:827-40.  
[\[PubMed Abstract\]](#) -

# Figures

**Figure 1 Transmission Categories for Females\* Living with HIV in United States, 2021**

\*Estimate for females ≥13 years of age living with diagnosed or undiagnosed HIV  
Other = perinatal acquisition, hemophilia, blood transfusion, and risk factor not reported or identified


Source: Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2017–2021. HIV Surveillance Supplemental Report. 2023;28(3). Published May 2023.



**Figure 2 Transmission Categories for Women\* with New HIV Infections in United States, 2021**

\*Estimate for females 13 years of age or older

Source: Centers for Disease Control and Prevention. Estimated HIV Incidence and Prevalence in the United States, 2017–2021. HIV Surveillance Supplemental Report. 2023;28(3). Published May 2023.



**Figure 3 Treatment of Trichomoniasis in Women with HIV**

Source: Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr. 2010;55:565-71.




Table 1.

### Intrauterine Devices Used for Contraception

| Device                               | Component in IUD       | Pregnancy Rate Year 1* | Approved Duration^ |
|--------------------------------------|------------------------|------------------------|--------------------|
| <b>Non-Hormonal Copper IUD</b>       |                        |                        |                    |
| <i>ParaGard</i>                      | Copper coil            | 0.60-0.80%             | 10 years           |
| <b>Levonorgestrel-Releasing IUDs</b> |                        |                        |                    |
| <i>Mirena</i>                        | 52 mg levonorgestrel   | 0.20%                  | 5 years            |
| <i>Liletta</i>                       | 52 mg levonorgestrel   | 0.15%                  | 6 years            |
| <i>Kyleena</i>                       | 19.5 mg levonorgestrel | 0.16%                  | 5 years            |
| <i>Skyla</i>                         | 13.5 mg levonorgestrel | 0.41%                  | 3 years            |

\* These year 1 pregnancy rates are based on information provided in prescribing information

^ Approved Duration = United States Food and Drug Administration (FDA) approved duration of use

Source:

- Curtis KM, Peipert JF. Long-Acting Reversible Contraception. N Engl J Med. 2017;376:461-468. [[PubMed Abstract](#)]



Table 2.

**Guidance for Contraceptive Use in Women at High Risk for HIV**

| Copper-Containing IUD* |              | LNG-IUD    |              | Implants | DMPA | POP | CHCs |
|------------------------|--------------|------------|--------------|----------|------|-----|------|
| Initiation             | Continuation | Initiation | Continuation |          |      |     |      |
| 1                      | 1            | 1          | 1            | 1        | 1    | 1   | 1    |

**\*Clarification with IUDs:** Many women at high risk for HIV are also at risk for other sexually transmitted diseases (STDs). For these women, refer to the recommendations in the “U.S. Medical Eligibility Criteria for Contraceptive Use” for women with other factors related to STDs and the “U.S. Selected Practice Recommendations for Contraceptive Use” on STD screening before IUD insertion.

**Evidence (IUDs):** High-quality evidence from one randomized clinical trial, along with low-quality evidence from two observational studies, suggested no increased risk for HIV acquisition with Cu-IUD use.§ No studies were identified for LNG-IUDs.¶

**Evidence (implants, DMPA, POP):** High-quality evidence from one randomized clinical trial observed no statistically significant differences in HIV acquisition between DMPA-IM versus Cu-IUD, DMPA-IM versus LNG implant, and Cu-IUD versus LNG implant.¶,\*\* Of the low-to-moderate-quality evidence from 14 observational studies, some studies suggested a possible increased risk for HIV with progestin-only injectable use, which was most likely due to unmeasured confounding.¶ Low-quality evidence from 3 observational studies did not suggest an increased HIV risk for implant users.¶ No studies of sufficient quality were identified for POPs.¶

**Evidence (CHCs):** Low-to-moderate-quality evidence from 11 observational studies suggested no association between COC use (it was assumed that studies that did not specify oral contraceptive type examined mostly, if not exclusively, COC use) and HIV acquisition.¶ No studies of patch, ring, or combined injectable contraception were identified.¶

**Abbreviations:** IUD= intrauterine device; LNG-IUD = levonorgestrel-releasing intrauterine device; DMPA = depot medroxyprogesterone acetate (injectable); POP = progestin-only pill; CHC = combined hormonal contraceptive

\*Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-3).

†Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65(No. RR-4).

§ Hannaford PC, Ti A, Chipato T, Curtis KM. Copper intrauterine device use and HIV acquisition in women: a systematic review. BMJ Sex Reprod Health. 2020;46:17–25.¶ Curtis KM, Hannaford PC, Rodriguez MI, Chipato T, Steyn PS, Kiarie JN. Hormonal contraception and HIV acquisition among women: an updated systematic review. BMJ Sex Reprod Health 2020;46:8–16.

\*\* Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial Consortium. HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomized, multicentre, open-label trial. Lancet 2019;394:303–13.

**Summary of Categories for classifying contraceptives**

1 = A condition for which there is no restriction for the use of the contraceptive method.

| Copper-Containing IUD*  |              | LNG-IUD    |              | Implants | DMPA | POP | CHCs |
|---|--------------|------------|--------------|----------|------|-----|------|
| Initiation  | Continuation | Initiation | Continuation |          |      |     |      |
| <p>2 = A condition for which the advantages of using the method generally outweigh the theoretical or proven risks.</p> <p>3 = A condition for which the theoretical or proven risks usually outweigh the advantages of using the method.</p> <p>4 = A condition that represents an unacceptable health risk if the contraceptive method is used.</p> |              |            |              |          |      |     |      |

Source:

- Tepper NK, Curtis KM, Cox S, Whiteman MK. Update to U.S. Medical Eligibility Criteria for Contraceptive Use, 2016: Updated Recommendations for the Use of Contraception Among Women at High Risk for HIV Infection. MMWR Morb Mortal Wkly Rep. 2020;69:405-10. [\[PubMed Abstract\]](#)

